Biomarker Core

项目总结-生物标志物核心 探索性范德比尔特阿尔茨海默病研究中心（VADRC）生物标志物核心将利用 范德比尔特在蛋白质组学、神经影像学和遗传学方面的机构优势可提供可扩展的 可以支持生物标志物收集、存储、分析、集成和分发的基础设施。下 在Timothy Hohman博士的领导下，我们将范德比尔特确立为临床前研究的基因组学核心。 阿尔茨海默病联盟，建立了生物标志物核心的多地点队列和尸检研究， 阿尔茨海默病和痴呆与谵妄相关，导致了多个大规模的发现和候选人 蛋白质组学分析强调了阿尔茨海默病风险和恢复力的新标志物，并建立了 阿尔茨海默病数据库的恢复力，一个协调液体的本地生物标志物数据库， 神经影像学和10多项独立队列研究的基因组数据。对于P20，我们将利用我们的 当地丰富的基础设施和资源，以获得强大的流体，神经成像和遗传生物标志物， VADRC内的临床核心和附属队列研究。生物标志物核心和临床核心将发挥作用 密切确保使用已建立的标准化方案适当收集相关生物标志物， 目前的最佳做法。流体、神经成像和遗传数据将在一个 建立关系数据库，生物标志物核心将努力确保适当的存储和处理 所有样本和数据，并采取多种质量控制措施。临床中心采集的样本 将由生物标志物核心整合到支持VADRC主题的资助，正在进行的项目中 重点是建立有效的预防和治疗策略，非淀粉样蛋白途径的损伤， 通常与阿尔茨海默病的核心病理同时发生。例子包括发现蛋白质组学项目 通过临床前阿尔茨海默病联盟的神经成像项目， 基因组学项目作为阿尔茨海默病遗传学联盟和阿尔茨海默病的一部分 测序项目。所有数据将与大规模队列研究协调，生物标志物核心将 与行政核心协调，分发所有生物标志物数据，以支持地方和国家研究 活动生物标志物核心还将促进生物标本收集、神经影像学、 加工和遗传学，以促进标准化的做法，并促进新的培训经验， 学生，研究员和教职员工生物标志物核心的独特定位是整合蛋白质组学，神经成像， 将VADRC的基因组数据管道纳入国家联盟的完善工作流程，并确保 VADRC仍然处于预防，大规模发现和治疗干预的最前沿。 阿尔茨海默氏病及相关痴呆症。

PROJECT SUMMARY – BIOMARKER CORE The Exploratory Vanderbilt Alzheimer’s Disease Research Center (VADRC) Biomarker Core will leverage Vanderbilt’s institutional strengths in proteomics, neuroimaging, and genetics to provide a scalable infrastructure that can support biomarker collection, storage, analysis, integration, and distribution. Under the leadership of Dr. Timothy Hohman, we have established Vanderbilt as the Genomics Core for the Preclinical Alzheimer’s Disease Consortium, established the Biomarker Core for a multi-site cohort and autopsy study of Alzheimer’s disease and dementia correlates of delirium, led multiple large-scale discovery and candidate proteomic analyses emphasizing novel markers of risk and resilience to Alzheimer’s disease, and established the Resilience from Alzheimer’s Disease database, a local biomarker data repository that harmonizes fluid, neuroimaging, and genomic data across 10+ independent cohort studies. For the P20, we will leverage our local rich infrastructure and resources to acquire robust fluid, neuroimaging, and genetic biomarkers for the Clinical Core and affiliated cohort studies within the VADRC. The Biomarker Core and Clinical Core will work closely to ensure proper collection of relevant biomarkers using established, standardized protocols reflecting current best practices. Fluid, neuroimaging, and genetic data will be processed and stored within an established relational database, and the Biomarker Core will work to ensure proper storage and processing of all samples and data, with multiple quality control measures in place. Samples collected by the Clinical Core will be integrated by the Biomarker Core into funded, ongoing projects that support the VADRC’s thematic focus on establishing effective prevention and treatment strategies for non-amyloid pathways of injury that commonly co-occur with core Alzheimer’s disease pathology. Examples include discovery proteomic projects using mass-spectrometry, neuroimaging projects through the Preclinical Alzheimer’s Disease Consortium, and genomics projects as part of the Alzheimer’s Disease Genetics Consortium and Alzheimer’s Disease Sequencing Project. All data will be harmonized with large-scale cohort studies, and the Biomarker Core will coordinate with the Administrative Core to distribute all biomarker data to support local and national research activities. The Biomarker Core will also promote educational activities in biospecimen collection, neuroimage processing, and genetics to promote standardized practices and facilitate novel training experiences for students, fellows, and faculty. The Biomarker Core is uniquely positioned to integrate proteomic, neuroimaging, and genomic data pipelines for the VADRC into well-established workflows from national consortia and ensure that the VADRC remains at the forefront of prevention, large-scale discovery, and therapeutic intervention of Alzheimer’s disease and related dementias.